MX2024003779A - Agentes de union dirigidos a celulas tumorales que expresan trop2. - Google Patents
Agentes de union dirigidos a celulas tumorales que expresan trop2.Info
- Publication number
- MX2024003779A MX2024003779A MX2024003779A MX2024003779A MX2024003779A MX 2024003779 A MX2024003779 A MX 2024003779A MX 2024003779 A MX2024003779 A MX 2024003779A MX 2024003779 A MX2024003779 A MX 2024003779A MX 2024003779 A MX2024003779 A MX 2024003779A
- Authority
- MX
- Mexico
- Prior art keywords
- trop2
- binding agents
- tumor cells
- expressing tumor
- agents targeting
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163249728P | 2021-09-29 | 2021-09-29 | |
| US202263326572P | 2022-04-01 | 2022-04-01 | |
| PCT/CA2022/051437 WO2023049999A1 (en) | 2021-09-29 | 2022-09-28 | Binding agents targeting trop2-expressing tumor cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024003779A true MX2024003779A (es) | 2024-04-19 |
Family
ID=85780298
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024003779A MX2024003779A (es) | 2021-09-29 | 2022-09-28 | Agentes de union dirigidos a celulas tumorales que expresan trop2. |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US20240360242A1 (https=) |
| EP (1) | EP4408893A4 (https=) |
| JP (1) | JP2024535930A (https=) |
| KR (1) | KR20240082383A (https=) |
| AU (1) | AU2022357634A1 (https=) |
| CA (1) | CA3231574A1 (https=) |
| IL (1) | IL311673A (https=) |
| MX (1) | MX2024003779A (https=) |
| TW (1) | TW202330605A (https=) |
| WO (1) | WO2023049999A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4408893A4 (en) | 2021-09-29 | 2026-02-18 | Kisoji Biotechnology Inc | Binding agents targeting tumor cells expressing too much 2 |
| CN121419995A (zh) * | 2023-04-04 | 2026-01-27 | 加拿大商木曾路生物科技公司 | 靶向表达trop2的肿瘤细胞的结合剂 |
| WO2024051383A1 (zh) * | 2023-07-28 | 2024-03-14 | 上海洛启生物医药技术有限公司 | 抗Trop2抗体、包含所述抗体的缀合物及其应用 |
| WO2026059880A1 (en) * | 2024-09-12 | 2026-03-19 | Modernatx, Inc. | Trop2 binding molecules, nucleic acids encoding same, and methods of use |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201500220A1 (ru) | 2010-05-17 | 2015-10-30 | Ливтех, Инк. | Антитело против trop-2 человека, обладающее противоопухолевой активностью in vivo |
| WO2011155579A1 (ja) | 2010-06-10 | 2011-12-15 | 北海道公立大学法人札幌医科大学 | 抗Ｔｒｏｐ－２抗体 |
| US9427464B2 (en) | 2011-11-22 | 2016-08-30 | Chiome Bioscience Inc. | Anti-human TROP-2 antibody having an antitumor activity in vivo |
| CN116199790A (zh) * | 2015-02-10 | 2023-06-02 | 米纳瓦生物技术公司 | 人源化抗MUCl*抗体 |
| EP3600283A4 (en) * | 2017-03-27 | 2020-12-16 | Immunomedics, Inc. | TREATMENT OF TROP-2 EXPRESSIVE TRIPLE NEGATIVE BREAST CANCER WITH SACITUZUMAB GOVITECAN AND A RAD51 INHIBITOR |
| GB201811368D0 (en) * | 2018-07-11 | 2018-08-29 | Ucb Biopharma Sprl | Antibody |
| CN112646038B (zh) * | 2019-10-11 | 2025-06-03 | 迈威(上海)生物科技股份有限公司 | 抗人Trop-2抗体及其应用 |
| EP4077374A4 (en) | 2019-12-20 | 2023-12-27 | Kisoji Biotechnology Inc. | POLYPEPTIDES, PROTEIN COMPLEXES AND METHODS FOR PRODUCING THE SAME |
| CN113527496B (zh) * | 2020-04-16 | 2022-03-04 | 上海洛启生物医药技术有限公司 | 抗Trop2纳米抗体及其应用 |
| CN112321715B (zh) * | 2020-11-03 | 2022-05-10 | 博奥信生物技术（南京）有限公司 | 抗trop2纳米抗体及其制备方法和应用 |
| CN114685669A (zh) | 2020-12-30 | 2022-07-01 | 和铂医药(苏州)有限公司 | 结合trop2的抗体及其用途 |
| EP4408893A4 (en) | 2021-09-29 | 2026-02-18 | Kisoji Biotechnology Inc | Binding agents targeting tumor cells expressing too much 2 |
-
2022
- 2022-09-28 EP EP22874016.3A patent/EP4408893A4/en active Pending
- 2022-09-28 JP JP2024519706A patent/JP2024535930A/ja active Pending
- 2022-09-28 MX MX2024003779A patent/MX2024003779A/es unknown
- 2022-09-28 IL IL311673A patent/IL311673A/en unknown
- 2022-09-28 CA CA3231574A patent/CA3231574A1/en active Pending
- 2022-09-28 KR KR1020247014071A patent/KR20240082383A/ko active Pending
- 2022-09-28 WO PCT/CA2022/051437 patent/WO2023049999A1/en not_active Ceased
- 2022-09-28 AU AU2022357634A patent/AU2022357634A1/en active Pending
- 2022-09-29 TW TW111137049A patent/TW202330605A/zh unknown
-
2024
- 2024-03-28 US US18/620,397 patent/US20240360242A1/en active Pending
- 2024-05-14 US US18/664,070 patent/US12338295B2/en active Active
- 2024-05-14 US US18/664,091 patent/US12275799B2/en active Active
- 2024-05-14 US US18/664,078 patent/US12371508B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022357634A1 (en) | 2024-05-09 |
| US20240317886A1 (en) | 2024-09-26 |
| US20240327537A1 (en) | 2024-10-03 |
| TW202330605A (zh) | 2023-08-01 |
| EP4408893A1 (en) | 2024-08-07 |
| EP4408893A4 (en) | 2026-02-18 |
| IL311673A (en) | 2024-05-01 |
| US12371508B2 (en) | 2025-07-29 |
| US12338295B2 (en) | 2025-06-24 |
| US20240317887A1 (en) | 2024-09-26 |
| US20240360242A1 (en) | 2024-10-31 |
| US12275799B2 (en) | 2025-04-15 |
| WO2023049999A1 (en) | 2023-04-06 |
| KR20240082383A (ko) | 2024-06-10 |
| CA3231574A1 (en) | 2023-04-06 |
| JP2024535930A (ja) | 2024-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024003779A (es) | Agentes de union dirigidos a celulas tumorales que expresan trop2. | |
| ZA202405748B (en) | Universal abt compounds and uses thereof | |
| WO2022081718A8 (en) | Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof | |
| EP4527466A3 (en) | Anti-dll3 chimeric antigen receptors and uses thereof | |
| PH12019501663A1 (en) | Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate | |
| MX2022000652A (es) | Anticuerpos contra claudina 18 y metodos de tratamiento del cancer. | |
| EP4566621A3 (en) | Dll3/cd3 binding proteins for the treatment of cancer | |
| EP4501352A3 (en) | Compositions and methods for car t cell therapy | |
| CR20200571A (es) | Moléculas de únion contra bcma y usos de las mismas | |
| MX2010005830A (es) | Conjugado de anticuerpo monoclonal anti-b7h4 - farmaco y metodos de uso del mismo. | |
| WO2019232477A3 (en) | Genome-edited invariant natural killer t (inkt) cells for the treatment of hematologic malignancies | |
| EP4389226A3 (en) | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof | |
| WO2019224716A8 (en) | Antibodies specific for gucy2c and uses thereof | |
| AU2018449846A8 (en) | An anti-B7-H3 antibody | |
| WO2010019702A3 (en) | Ddr1-binding agents and methods of use thereof | |
| UA103202C2 (ru) | Фармацевтическая композиция опухолеассоциированных пептидов и ее применение для лечения раковых заболеваний | |
| BR112022005114A2 (pt) | Anticorpo, composição farmacêutica, métodos para tratar câncer e para produzir um conjugado anticorpo-fármaco e um anticorpo, ácido nucleico, vetor, célula hospedeira, e, conjugado anticorpo-fármaco | |
| CL2007003649A1 (es) | Un conjugado de molecula asociado a anticuerpo monoclonal humano anti-cd70; composicion que comprende al conjugado de molecula asociado a anticuerpo; metodo de inhibicion del crecimiento de celulas tumorales que expresan cd70. | |
| EP3593812A3 (en) | Treatment of cancer using chimeric antigen receptor | |
| NZ737726A (en) | Multispecific antigen-binding molecules and uses thereof | |
| WO2021127200A8 (en) | Ilt3-binding agents and methods of use thereof | |
| UA99602C2 (ru) | Антитело, специфически связывающееся с jam-a, способное ингибировать пролиферацию опухолевых клеток | |
| CR20240415A (es) | MOLÉCULAS DE UNIÓN CONTRA FRa | |
| MX2022005821A (es) | Terapia del carcinoma de celulas renales (rcc) usando linfocitos t modificados por ingenieria genetica dirigidos a cd70. | |
| NZ761636A (en) | Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods |